Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply

MLA

Sara, Rundquist, et al. “Letter: Vedolizumab or a Second Anti-TNF-No Difference in Efficacy for Primary Biologic Failures with IBD. Authors’ Reply.” Alimentary PharmacologytherapeuticsREFERENCES, vol. 53, no. 9, Apr. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........5e6b7a8a2a32b4b154be54ad7ab6b506&authtype=sso&custid=ns315887.

APA

Sara, R., Michael C, S., Carl, E., Ola, O., Scott, M., & Jonas, H. (2021). Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors’ reply. Alimentary PharmacologytherapeuticsREFERENCES, 53(9).

Chicago

Sara, Rundquist, Sachs Michael C, Eriksson Carl, Olén Ola, Montgomery Scott, and Halfvarson Jonas. 2021. “Letter: Vedolizumab or a Second Anti-TNF-No Difference in Efficacy for Primary Biologic Failures with IBD. Authors’ Reply.” Alimentary PharmacologytherapeuticsREFERENCES 53 (9). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........5e6b7a8a2a32b4b154be54ad7ab6b506&authtype=sso&custid=ns315887.